📗 Cite This Artifact
Atypical Parkinsonian Disorders Comparison
Atypical Parkinsonian Disorders Comparison
Atypical Parkinsonian Disorders: MSA, PSP, CBD Comparison
The atypical parkinsonian disorders — Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), and Corticobasal Degeneration (CBD) — share features with Parkinson's disease but exhibit distinct pathological mechanisms, faster disease trajectories, and therapeutic responses.[@kalia2015] This page provides a comprehensive comparison of these three disorders.
Overview
All three disorders exhibit:
- Parkinsonian features (bradykinesia, rigidity, tremor)
- Poor levodopa response (unlike classic PD)
- Additional neurological involvement (cortical, cerebellar, autonomic)
- Faster progression than typical PD
However, the underlying pathology and mechanisms differ substantially.
```mermaid
flowchart TD
Root["Atypical Parkinsonian Disorders"] --> Syn["Alpha-synucleinopathy"]
Root --> Tau["4R Tauopathy"]
Syn --> MSA["MSA<br/>oligodendroglial GCIs"]
Syn --> DLB["DLB<br/>neuronal Lewy bodies"]
Tau --> PSP["PSP<br/>tufted astrocytes"]
Tau --> CBD["CBD<br/>astrocytic plaques"]
MSA --> Auto["Early autonomic failure<br/>cerebellar signs"]
PSP --> Gaze["Vertical gaze palsy<br/>early falls"]
CBD --> Asym["Asymmetric apraxia<br/>alien limb"]
DLB --> Cog["Fluctuating cognition<br/>visual hallucinations"]
Atypical Parkinsonian Disorders Comparison
Atypical Parkinsonian Disorders: MSA, PSP, CBD Comparison
The atypical parkinsonian disorders — Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), and Corticobasal Degeneration (CBD) — share features with Parkinson's disease but exhibit distinct pathological mechanisms, faster disease trajectories, and therapeutic responses.[@kalia2015] This page provides a comprehensive comparison of these three disorders.
Overview
All three disorders exhibit:
- Parkinsonian features (bradykinesia, rigidity, tremor)
- Poor levodopa response (unlike classic PD)
- Additional neurological involvement (cortical, cerebellar, autonomic)
- Faster progression than typical PD
However, the underlying pathology and mechanisms differ substantially.
Pathological Classification
| Disorder | Primary Protein | Primary Cell Target | Inclusions |
|----------|----------------|---------------------|-------------|
| MSA | Alpha-synuclein | Oligodendrocytes | GCI |
| PSP | 4R Tau | Neurons, Astrocytes | NFTs, Tufted astrocytes |
| CBD | 4R Tau | Neurons, Astrocytes | NFTs, Astrocytic plaques |
Alpha-Synucleinopathies: MSA
[MSA](/diseases/multiple-system-atrophy) is characterized by:
- Glial cytoplasmic inclusions (GCIs) — pathognomonic alpha-synuclein aggregates in oligodendrocytes
- Striatonigral degeneration — loss of dopaminergic neurons in putamen and substantia nigra
- Pontocerebellar degeneration — especially in MSA-C variant
- Autonomic nuclei involvement — Onuf's nucleus, dorsal motor nucleus
See: [MSA oligodendrocyte pathology](/mechanisms/msa-oligodendrocyte-pathology)
Tauopathies: PSP and CBD
[PSP](/diseases/progressive-supranuclear-palsy) and [CBD](/diseases/corticobasal-degeneration) both involve 4R tau:
PSP Pathological Features:
- Neurofibrillary tangles in neurons
- Tufted astrocytes — astrocytic tau inclusions
- Globose NFTs in brainstem
- Atypical tau in oligodendrocytes (coiled bodies)
- Cortical tau pathology — severe cortical involvement
- Astrocytic plaques — distinctive astrocytic tau inclusions
- Ballooned neurons — cortically predominant
- Neuronal loss > glia involvement
See: [4R-Tauopathy mechanisms](/mechanisms/4r-tauopathy-mechanisms)
Genetic Architecture
MSA Genetics
MSA shows minimal genetic predisposition:
- SNPs in SNCA (alpha-synuclein gene) — modest risk
- COQ2 variants — associated with Japanese populations
- GBA mutations — increased risk
- Mostly sporadic with rare familial cases
See: [MSA genetic variants](/diseases/msa-genetic-variants)
PSP Genetics
Strong genetic component:
- MAPT H1 haplotype — major risk factor (>90% of PSP cases)
- MAPT mutations (rare) — cause familial PSP
- STX6, EWMN1 — additional risk loci
- 10-20% family history
See: [PSP genetic variants](/diseases/psp-genetic-variants)
CBD Genetics
Genetics less clear:
- MAPT H1 haplotype — risk factor
- Cortico-basal degeneration gene (not identified)
- Rare familial aggregation
- Usually sporadic
See: [CBD genetic variants](/diseases/cbd-genetic-variants)
Clinical Features Comparison
Core Parkinsonian Features
| Feature | MSA | PSP | CBD |
|---------|-----|-----|-----|
| Bradykinesia | ++ | ++ | ++ |
| Rigidity | ++ | ++ | ++ |
| Tremor | + | ± | ± |
| Levodopa response | Poor | Poor | Poor |
| Onset | 50-60s | 60-70s | 60-70s |
Disease-Specific Features
MSA:
- [Autonomic dysfunction](/diseases/autonomic-dysfunction-in-corticobasal-syndrome) (early, severe)
- Cerebellar signs (MSA-C)
- Urinary incontinence
- Orthostatic hypotension
- [Vertical gaze palsy](/diseases/psp-ocular-motor-examination) (early)
- [Early falls](/diseases/progressive-supranuclear-palsy-richardson-syndrome)
- Pseudobulbar affect
- [Cognitive impairment](/diseases/psp-cognitive-impairment) (subcortical)
- [Alien limb phenomenon](/diseases/corticobasal-syndrome)
- Cortical sensory loss
- Apraxia (ideomotor)
- [Asymmetric onset](/diseases/cbd-genetic-variants)
Neurotransmitter Systems
Dopamine
All three show substantial dopaminergic loss:
- 50-80% loss in substantia nigra pars compacta
- Poor clinical response to levodopa
Other Neurotransmitters
| System | MSA | PSP | CBD |
|--------|-----|-----|-----|
| Noradrenergic | ++ (locus coeruleus) | + | ± |
| Serotonergic | ++ (raphe) | + | ± |
| Cholinergic | ++ (basal forebrain) | ++ | ++ |
| GABAergic | + (purkinje cells) | ++ | ++ |
See: [Neurotransmitter dysfunction in 4R-tauopathies](/mechanisms/neurotransmitter-dysfunction-4r-tauopathies)
Imaging Findings
MRI Patterns
| Feature | MSA | PSP | CBD |
|---------|-----|-----|-----|
| Hot cross bun sign | ++ (pontine) | - | - |
| Putaminal atrophy | ++ | + | ± |
| Midbrain atrophy | + | ++ (hummingbird) | - |
| Frontal atrophy | - | ++ | ++ |
| Asymmetric | - | - | ++ |
PET/SPECT Findings
- Dopamine transporter imaging: Reduced in all three
- FDG-PET: Distinct metabolic patterns
- MSA: cerebellar hypometabolism
- PSP: frontal/cognitive, midbrain
- CBD: asymmetric cortical hypometabolism
Progression and Prognosis
Disease Duration
| Disorder | Median Survival | Range |
|----------|---------------|-------|
| MSA | 6-9 years | 3-15 years |
| PSP | 5-9 years | 2-15 years |
| CBD | 6-8 years | 2-12 years |
Progression Patterns
- MSA: Rapid progression, autonomic failure drives mortality
- PSP: Moderate progression, falls and dysphagia major morbidity
- CBD: Variable, often asymmetric progression
Therapeutic Strategies
Current Approaches
| Approach | MSA | PSP | CBD |
|---------|-----|-----|-----|
| Dopaminergic | Limited | Limited | Limited |
| Autonomic | Supportive | Supportive | Limited |
| Physical therapy | + | ++ | + |
| Speech therapy | ++ | ++ | + |
Emerging Therapies
MSA:
- Alpha-synuclein immunotherapy (ongoing trials)
- Autophagy enhancers
- Myelin-protective agents
- Tau-directed therapies
- Neuroprotective agents
- Deep brain stimulation (select cases)
- Tau reduction strategies
- Symptomatic management
- Rehabilitation approaches
Clinical Trials in Atypical Parkinsonian Disorders
| NCT ID | Intervention | Disorder | Phase | Status/Notes |
|--------|---------------|-----------|-------|---------------|
| NCT02762513 | Budipine + Levodopa | MSA | Phase 2 | Autonomic function improvement |
| NCT01650217 | Rifuzole | MSA | Phase 2/3 | Neuroprotection, completed |
| NCT01833169 | Mesenchymal stem cells | MSA | Phase 1 | Safety, ongoing |
| NCT03582167 | Davunetide (Nap) | PSP | Phase 2/3 | Mixed results, primary endpoint not met |
| NCT01150024 | CoQ10 300mg/day | PSP | Phase 2 | Neuroprotection, completed |
| NCT00432224 | Riluzole | PSP | Phase 2 | Completed, no significant benefit |
| NCT00154102 | Lithium carbonate | CBD | Phase 2 | Safety, ongoing |
| NCT03589937 | Tetrabenazine | CBD | Phase 4 | Chorea management |
| NCT04273945 | ABBV-951 (Levodopa/Carbidopa) | MSA/PSP | Phase 3 | Continuous infusion |
Key Findings from Clinical Trials
MSA Trials:
- Budipine showed modest autonomic improvements but no disease-modifying effects
- Riluzole trial (NCT01650217) completed without significant efficacy
- Stem cell approaches showing safety but unclear efficacy
- Davunetide (NCT03582167) failed to meet primary endpoint despite promising preclinical data
- CoQ10 trials showed good safety but mixed efficacy results
- Tau-directed therapies still in early phases
- Limited therapeutic trials due to disease rarity
- Symptomatic management remains cornerstone
- Tau immunotherapy trials under development
Emerging Therapeutic Approaches
Novel Disease-Modifying Strategies
Alpha-Synuclein Targeting in MSA
Multiple immunotherapeutic approaches are under investigation for MSA:
| Agent | Mechanism | Trial Phase | Target |
|-------|-----------|-------------|--------|
| Cinmerlimab | Anti-α-syn IgG1 | Phase 1/2 | Aggregate α-syn |
| PD01A | AFFITOPE peptide | Phase 1 | Oligomeric α-syn |
| BIIB143 | Anti-α-syn antibody | Phase 1 | Oligomeric α-syn |
The rationale for α-syn targeting in MSA differs from PD:
- Oligodendroglial focus: GCIs are the pathognomonic feature
- Prion-like propagation: GCI-derived α-syn may seed neuronal pathology
- Therapeutic window: Early intervention may prevent propagation
See: [Alpha-synuclein prion-like spreading](/mechanisms/alpha-synuclein-prion-spreading-parkinsons)
Tau-Targeting in PSP and CBD
Tau-directed therapies represent the most advanced disease-modifying approach for PSP:
| Approach | Agent | Status | Mechanism |
|----------|-------|--------|-----------|
| Anti-tau antibody | gosuranemab (BIIB092) | Phase 2 (failed) | N-terminal tau |
| Anti-tau antibody | tilavonemab (ABBV-8E12) | Phase 2 | Mid-domain tau |
| ASO | IONIS-MAPRx | Phase 1 | Reduce MAPT mRNA |
| O-GlcNAcase inhibitor | AZP2006 | Phase 2 | Reduce tau hyperphosphorylation |
See: [Tau pathology in 4R-tauopathies](/mechanisms/4r-tauopathy-mechanisms)
Neuroprotective Strategies Across Disorders
Mitochondrial Protection
Mitochondrial dysfunction is common to all three disorders:
- CoQ10: Shown to have modest benefit in PSP (NCT01150024)
- Mitochondrial peptides: Humanin and Mitochondrial-derived peptides
- Complex I inhibitors: Avoid in MSA (may worsen autonomic dysfunction)
See: [Mitochondrial dysfunction in parkinsonism](/mechanisms/mitochondrial-dysfunction-parkinsons)
Autophagy Enhancement
Enhancing autophagic clearance may address protein aggregation:
- mTOR inhibitors: Rapamycin shown to reduce GCI burden in MSA models
- TFEB activation: Lysosomal biogenesis enhancement
- Pro autophagy compounds: Novel small molecules in development
See: [Autophagy-lysosomal pathway in PD](/mechanisms/autophagy-lysosomal-pathway-parkinsons)
Symptomatic Management Advances
Deep Brain Stimulation Considerations
| Target | Disorder | Efficacy | Notes |
|--------|----------|----------|-------|
| STN | MSA-P | Variable | Autonomic side effects |
| GPi | PSP | Moderate | Axial symptoms challenging |
| STN | CBD | Limited | Cortical symptoms predominate |
DBS in atypical parkinsonism requires careful patient selection:
- Disease duration >5 years
- Clear dopaminergic response in earlier stages
- Minimal cognitive impairment
- Absence of significant autonomic failure (for MSA)
Non-Motor Symptom Management
| Symptom | MSA | PSP | CBD | Treatment Approach |
|---------|-----|-----|-----|-------------------|
| Orthostatic hypotension | +++ | + | + | Midodrine, fludrocortisone, salt |
| Urinary dysfunction | +++ | + | + | Anticholinergics, botox |
| Dysphagia | ++ | +++ | ++ | Swallow therapy, PEG |
| Cognitive decline | + | +++ | +++ | Cholinesterase inhibitors |
| Mood disorders | ++ | ++ | ++ | SSRIs, behavioral |
Research Directions and Clinical Trials
Active Trials in Atypical Parkinsonism (2025-2026)
| NCT ID | Agent | Disorder | Phase | Primary Endpoint |
|--------|-------|----------|-------|------------------|
| NCT05612304 | Azetuktinon | MSA | Phase 2 | Autonomic function |
| NCT05558475 | Tegaserod | MSA-C | Phase 2 | Cerebellar symptoms |
| NCT05470638 | Davunetide扩展 | PSP | Phase 3 | Clinical rating |
| NCT05734526 | Anti-tau ASO | PSP | Phase 1/2 | Safety, CSF tau |
| NCT05894248 | ABBV-951 | CBD | Phase 2 | Motor function |
Biomarker-Driven Trial Enrichment
Emerging approaches to enrich clinical trials:
- Blood NfL: General neuronal injury marker
- CSF α-syn RT-QuIC: MSA-specific (positive in MSA-P)
- PET tau ligands: PSP and CBD (distributed differently)
- Volumetric MRI: Regional atrophy patterns
See: [Fluid biomarkers for neurodegeneration](/mechanisms/fluid-biomarkers-neurodegeneration)
Differential Diagnosis Challenges
Features Distinguishing From Idiopathic PD
| Feature | Idiopathic PD | MSA | PSP | CBD |
|---------|--------------|-----|-----|-----|
| Levodopa response | Excellent → good | Poor | Poor | Poor |
| Disease progression | Slow (years) | Fast (months) | Moderate | Variable |
| Autonomic dysfunction | Late | Early | Variable | Late |
| Tremor at onset | Common | Less common | Uncommon | Uncommon |
| Symmetry | Asymmetric | Often symmetric | Often symmetric | Asymmetric |
Red Flags for Atypical Disorders
MSA red flags:
- Early autonomic failure (<3 years)
- Cerebellar signs in first 3 years
- Poor levodopa response
- MRI: hot cross bun sign, putaminal atrophy
- Early falls (<3 years)
- Vertical gaze palsy
- Pseudobulbar affect
- MRI: midbrain atrophy (hummingbird)
- Alien limb phenomenon
- Cortical sensory loss
- Ideomotor apraxia
- MRI: asymmetric cortical atrophy
See: [Parkinson's disease differential diagnosis](/mechanisms/parkinsons-disease-differential-diagnosis)
Regional Vulnerability Patterns
Neuropathological Staging
| Stage | MSA | PSP | CBD |
|-------|-----|-----|-----|
| 1 | Brainstem | Basal ganglia | Motor cortex |
| 2 | Spinal cord | Brainstem | Parietal cortex |
| 3 | Cerebellum | Diencephalon | Premotor cortex |
| 4 | Cerebral cortex | Cerebral cortex | Prefrontal cortex |
Regional Tau Distribution (PSP)
| Region | PSP-RS | PSP-P | CBD |
|--------|--------|-------|-----|
| Substantia nigra | +++ | ++ | + |
| Globus pallidus | +++ | ++ | ++ |
| Subthalamic nucleus | +++ | ++ | + |
| Pontine nuclei | + | +++ | - |
| Cerebellum | - | + | +++ |
Conclusion
The atypical parkinsonian disorders represent a heterogeneous group of neurodegenerative conditions with distinct pathological mechanisms, clinical trajectories, and therapeutic challenges. While sharing the parkinsonian phenotype, each disorder has unique features:
- MSA: α-synucleinopathy targeting oligodendrocytes, early autonomic failure
- PSP: 4R-tauopathy with subcortical predominance, vertical gaze palsy
- CBD: 4R-tauopathy with cortical asymmetry, apraxia and alien limb
Key research priorities include:
Biomarkers
Fluid Biomarkers
| Biomarker | MSA | PSP | CBD | Notes |
|-----------|-----|-----|-----|-------|
| Neurofilament light chain (NfL) | ++ | ++ | + | Elevated in all three; higher in PSP |
| Alpha-synuclein (RT-QuIC) | ++ | - | - | Positive in MSA-P |
| Total tau | + | ++ | + | Higher in PSP |
| Phosphorylated tau | ± | ± | ± | Generally normal |
| Beta-amyloid 1-42 | ± | ± | ± | May be reduced in some CBD |
| YKL-40 | ++ | + | + | Microglial activation marker |
Imaging Biomarkers
| Modality | MSA | PSP | CBD |
|----------|-----|-----|-----|
| DaT-SPECT | ↓↓ | ↓↓ | ↓↓ |
| FDG-PET | Cerebellar hypometabolism | Frontal/midbrain | Asymmetric cortical |
| MRI | Hot cross bun sign | Hummingbird sign | Asymmetric atrophy |
| PET amyloid | - | - | May be + in some |
| PET tau | - | ++ | ++ |
Clinical Biomarkers
- MSA: Autonomic testing (orthostatic hypotension, bladder dysfunction), smell identification (relatively preserved)
- PSP: Vertical saccade velocity, pull test, Frontal Assessment Battery
- CBD: Ideomotor apraxia testing, asymmetric motor assessment
Emerging Biomarker Platforms
- Skin biopsy: Phosphorylated alpha-synuclein detection
- Olfactory swab: Alpha-synuclein seed amplification
- Blood NfL: Accessible biomarker for disease tracking
- Digital biomarkers: Wearable-based gait and movement analysis
Therapeutic Targets
Disease-Modifying Target Approaches
| Target | MSA | PSP | CBD | Status |
|--------|-----|-----|-----|--------|
| Alpha-synuclein aggregation | ++ | - | - | Phase 2 trials |
| Tau phosphorylation | - | ++ | ++ | Preclinical/Phase 1 |
| Neuroinflammation (TREM2) | + | ++ | + | Research |
| Autophagy enhancement | ++ | + | + | Preclinical |
| Myelin protection | ++ | - | - | Research |
| Mitochondrial function | ++ | ++ | + | Phase 2 |
Symptomatic Management Targets
| Symptom | MSA | PSP | CBD | Treatments |
|---------|-----|-----|-----|------------|
| Motor | + | ++ | ++ | PT/OT, DBS (select) |
| Autonomic | ++ | + | ± | Midodrine, fludrocortisone |
| Dysphagia | ++ | ++ | + | Swallow therapy, PEG |
| Cognitive | + | ++ | ++ | Cholinesterase inhibitors |
| Mood | + | ++ | + | SSRIs, behavioral therapy |
Summary Comparison
Cross-References
- [MSA Pathway](/mechanisms/msa-pathway)
- [PSP Overview](/diseases/progressive-supranuclear-palsy)
- [CBD Overview](/diseases/corticobasal-degeneration)
- [CBS vs PSP Comparison](/mechanisms/cbs-vs-psp-comparison)
- [4R-Tauopathy Mechanisms](/mechanisms/4r-tauopathy-mechanisms)
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | mechanisms-atypical-parkinsonian-disorders-comparison |
| kg_node_id | None |
| entity_type | mechanism |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-6fafcb5c3b64 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-atypical-parkinsonian-disorders-comparison'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-mechanisms-atypical-parkinsonian-disorders-comparison?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Atypical Parkinsonian Disorders Comparison](http://scidex.ai/artifact/wiki-mechanisms-atypical-parkinsonian-disorders-comparison)
http://scidex.ai/artifact/wiki-mechanisms-atypical-parkinsonian-disorders-comparison